Add
AGEN to Portfolio
Set Alert
Email to a
Friend
| |||
|
|
Quotes & Info
|
| AGEN > SEC Filings for AGEN > Form 8-K on 27-Feb-2013 | All Recent SEC Filings |
27-Feb-2013
Other Events, Financial Statements and Exhibits
Agenus Inc. announced today that it has completed patient screening in its Phase 2 randomized, double-blind, multicenter study for HerpV, a recombinant "off-the-shelf" therapeutic vaccine candidate for the treatment of genital herpes in herpes simplex virus-2 (HSV-2) positive patients. HerpV contains Agenus' QS-21 Stimulon® adjuvant (QS-21 Stimulon). The Phase 2 study (designated as protocol C-400-02) has screened over 100 HSV-2 positive subjects and enrollment has been closed. The study will test the biological efficacy of HerpV as measured by effect on genital viral shedding after three injections of the therapeutic vaccine. A booster injection of HerpV will be given at six months after treatment to evaluate the potential durability of treatment effect.
The full text of the press release issued in connection with the announcement is being filed as Exhibit 99.1 to this current report on Form 8-K.
(d) Exhibits
The following exhibit is filed herewith:
99.1 Press Release dated February 27, 2013
|
|